TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.9% ·
share flow -5.3% ·
net new positions +5.6%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.15M | $67.79M | n/a | −1 |
| Q2 2026 | 113 | +16 | 68.20M | $3.64B | +20 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.17M | n/a | $120.90M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 5.99M | n/a | $88.72M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 3.48M | -4.5% | $51.55M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 2.78M | +27.4% | $41.20M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 2.50M | -7.7% | $36.93M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 2.00M | +1.4% | $29.66M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 1.13M | -34.0% | $16.74M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 1.07M | n/a | $15.80M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 9 | Two Sigma Investments ✦ | 918.71K | +19.5% | $13.60M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Marshall Wace ✦ | 742.73K | New | $10.99M | 0.0% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 711.26K | +35.6% | $10.53M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | AQR Capital Management ✦ | 228.09K | -42.9% | $3.38M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 13 | Millennium Management ✦ | 208.99K | +249.3% | $3.09M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 167.90K | New | $2.48M | 0.0% | New | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 71.37K | +33.9% | $1.06M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Norges Bank ✦ (passive) | 71.00K | 0.0% | $1.05M | 0.0% | Held | 5 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 43.18K | 0.0% | $639,093 | 0.0% | Held | 5 | SEC ↗ |
| 18 | Wellington Management ✦ | 35.01K | +5.5% | $518,132 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $10.99M | 0.0% |
| Point72 Asset Management | $2.48M | 0.0% |
Exited
| Viking Global Investors | $46.63M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 121.20K shares, $3,600 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 78.40K sh · $4.31M
Officer, Director · 37.27K sh · $2.02M
Officer, Director · 128.06K sh · $6.78M
Officer · 8.28K sh · $538,917
Officer, Director · 101.69K sh · $6.57M
Officer, Director · 6.80K sh · $441,795
Officer, Director · 99.72K sh · $6.31M
Officer · 79.11K sh · $5.04M
Officer · 93.60K sh · $5.92M
Officer, Director · 96.12K sh · $6.12M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology